Regional-Dependent Intestinal Permeability and BCS Classification: Elucidation of pH-Related Complexity in Rats Using Pseudoephedrine
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 2
Abstract
Based on its lower Log P value relative to metoprolol, a marker for the low/high-permeability (Peff) class boundary, pseudoephedrine was provisionally classified as BCS low-permeability compound. On the other hand, following oral administration, pseudoephedrine fraction dose absorbed (Fabs) and systemic bioavailability approaches 100%. This represents a challenge to the generally recognized Peff–Fabs correlation. The purpose of this study was to elucidate the underlying mechanisms behind the confusion in pseudoephedrine’s BCS classification. Pseudoephedrine’s BCS solubility class was determined, and its physicochemical properties and intestinal permeability were thoroughly investigated, both in vitro and in vivo in rats, considering the complexity of the whole of the small intestine. Pseudoephedrine was found to be unequivocally a high-solubility compound. All of the permeability studies revealed similar phenomenon; at any given intestinal segment/pH, the permeability of metoprolol was higher than that of pseudoephedrine, however, as the intestinal region becomes progressively distal, and the pH gradually increases, pseudoephedrine’s permeability rises above that of metoprolol in the former segment. This unique permeability pattern likely explains pseudoephedrine’s complete absorption. In conclusion, pseudoephedrine is a BCS Class I compound; no discrepancy between Peff and Fabs is involved in its absorption. Rather, it reflects the complexity behind Peff when considering the whole of the intestine. We propose to allow high-permeability classification to drugs with Peff that matches/exceeds the low/high class benchmark anywhere throughout the intestinal tract and not restricted necessarily to the jejunum.
Authors and Affiliations
Moran Fairstein, Rotem Swissa, Arik Dahan
Keywords
Related Articles
- EP ID EP681108
- DOI 10.1208/s12248-013-9462-x
- Views 102
- Downloads 0
The pharmacokinetics of escitalopram in patients with hepatic impairment
The effect of hepatic impairment on the pharmacokinetics of escitalopram was determined by means of nonlinear mixed effect modeling, considering both the Child-Pugh classification (and its components) and cytochrome P450...
Hepatic Metabolism and Disposition of Baicalein via the Coupling of Conjugation Enzymes and Transporters—In Vitro and In Vivo Evidences
Baicalein (Ba) was found to be subject to serious first-pass metabolism after oral administration. We previously revealed the important role of intestine in the low oral bioavailability of Ba. The present study aims to e...
Recent Advances in Structure-Based Virtual Screening of G-Protein Coupled Receptors
In addition to the rhodopsin crystal structure, high-resolution crystal structures of ligand-mediated G-protein-coupled receptors (GPCRs) have recently become available, and these have become attractive templates for dev...
Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFNγ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice
The online version of this article (doi:10.1208/s12248-012-9423-9) contains supplementary material, which is available to authorized users.
Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection
Antibody drug conjugates (ADCs) are a multi-component modality comprising of an antibody targeting a cell-specific antigen, a potent drug/payload, and a linker that can be processed within cellular compartments to releas...